Two additional 2,500-liter bioreactors
DP capacity to increase by up to 170%...introduction of isolator
St. Gen Biotech announced in a regulatory filing on the 26th that it has decided to expand its first plant in order to respond to growing demand for high-value biopharmaceuticals.
The company plans to invest approximately 110 billion won to expand production facilities for drug substances (DS) and drug products (DP), and to build related infrastructure. The investment period is expected to be about 27 months, from the first quarter of this year through the first quarter of 2028. Once the expansion is completed, annual production capacity will increase from the current 9,000 liters to 14,000 liters.
In this expansion, St. Gen Biotech will install two 2,500-liter bioreactors and one harvest unit. It will also introduce one isolator line to improve production quality. An isolator can fundamentally eliminate aseptic risks by completely blocking operator intervention during the filling process. The company explained that this is a strategic investment to meet the increasingly stringent standards of global companies.
As a result of this expansion, maximum DS production capacity will increase by 44%, and maximum DP production capacity will increase by 170%.
A St. Gen Biotech official said, "We plan to strengthen our strategy of selection and concentration on high value-added products, based on certifications from global regulatory agencies and our commercialization experience," adding, "By advancing our production capabilities, we will flexibly respond to global clients' needs from various development stages through to the commercial stage, thereby securing both stability and scalability."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
